Nivolumab (Anti-PD-1; Bms-936558, Ono-4538) in patients with advanced non-small cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis Meeting Abstract
| Authors: | Rizvi, N. A.; Gettinger, S. N.; Horn, L.; Gandhi, L.; Spigel, D. R.; Powderly, J. D.; Heist, R. S.; Carvajal, R. D.; Jackman, D. M.; Sequist, L. V.; Smith, D. C.; Leming, P. D.; Topalian, S. L.; Hodi, F. S.; Sznol, M.; Harbison, C. T.; Kollia, G. D.; Brahmer, J. R.; Antonia, S. J. |
| Abstract Title: | Nivolumab (Anti-PD-1; Bms-936558, Ono-4538) in patients with advanced non-small cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis |
| Meeting Title: | 6th Latin American Conference on Lung Cancer (LALCA) |
| Keywords: | erlotinib; chemotherapy; immunotherapy; nivolumab |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 9 |
| Issue: | 9 Suppl. 3 |
| Meeting Dates: | 2014 Aug 21-23 |
| Meeting Location: | Lima, Peru |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-09-01 |
| Start Page: | S152 |
| Language: | English |
| ACCESSION: | WOS:000344627100002 |
| PROVIDER: | wos |
| DOI: | 10.1097/01.JTO.0000454720.94093.d1 |
| Notes: | Meeting Abstract: O.1 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
